May 9 |
Akebia Therapeutics, Inc. (AKBA) Q1 2024 Earnings Call Transcript
|
May 9 |
Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
|
May 9 |
Akebia GAAP EPS of -$0.09 misses by $0.01, revenue of $32.6M misses by $13.49M
|
May 9 |
Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
May 8 |
Akebia Q1 2024 Earnings Preview
|
May 2 |
Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights
|
Apr 28 |
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
|
Apr 4 |
Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
|
Apr 2 |
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Apr 2 |
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
|